foxo4-dri senolytic human trial Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment FOXO4-DRI 10mg vial - Description
FOXO4 DRI 10mg vial Description RCpeptides Tools to eliminate senescent cells Nature Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology
Pay in 4 interest-free payments of $6.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



